FGF7 and neoplasm: Moreover, although the study demonstrates the efficacy of neutralizing antibodies targeting CAFs-derived FGF7 in reducing tumor growth in vivo, more research is needed to evaluate the long-term safety, potential side effects, and optimal dosing strategies of such therapeutic interventions.